Overview
Drug Use Investigation Of Gabapentin
Status:
Completed
Completed
Trial end date:
2014-05-01
2014-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of the this surveillance is to collect information about 1)adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Treatments:
Gabapentin
gamma-Aminobutyric Acid
Criteria
Inclusion Criteria:Patients need to be taking Gabapentin in order to be enrolled in the surveillance
Exclusion Criteria:
Patients not taking Gabapentin